(Reuters) -Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease ...

The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term. That's according to new data ...

Here are five things to know: Leqembi is meant only for people in the very early stages of Alzheimer’s disease. Alzheimer’s disease affects more than 6 million Americans.

While the drugs cannot cure or reverse the symptoms, they can slow the progression of the disease. Read more at ...

The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease. The ...

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

Leqembi, a drug that can help treat adult patients with Alzheimer’s, was given traditional approval by the FDA on Thursday. It was first approved in January for clinical trials.

A treatment for Alzheimer’s disease is on its way to many more patients across the U.S. The Food and Drug Administration on Thursday granted full approval to Leqembi, allowing Medicare enrollees ...

Additionally, Leqembi isn't cheap. The annual cost is $26,500. Medicare will cover 80% of that, but unless they have supplemental insurance or also are covered by Medicaid, many patients will have ...

By contrast, Leqembi, in an 18-month trial, showed unambiguous, if modest, benefits, slowing disease progression by about 27 percent, or roughly five months. The drug, administered every other ...

Alzheimer's drug Leqembi – a treatment proven to slow the clinical aspects of the progressive disease – could soon be available at several major U.S. health care systems. The Food and Drug ...

The Food and Drug Administration’s decision to grant accelerated approval for the anti-Alzheimer’s drug lecanemab, which will be sold as Leqembi, has significant potential for research into ...